Therarchon grows series A to $40m

Bpifrance has joined a consortium of investors that already featured Inserm Transfer Initiative and that previously provided $35m in funding.

Therachon, a Switzerland-based biotech developer focused on rare genetic diseases, closed its series A round at $40m yesterday following a $5m extension that featured Bpifrance, the public investment bank of France.

In September 2015, Inserm Transfer Initiative, the investment arm of state-owned biomedical and public health research institute Inserm, participated in a first tranche of $35m. The initial close was led by Orbimed and also included New Enterprise Associates and Versant Ventures.

Therachon is working on therapies for rare genetic diseases for which currently no treatments exist. The company’s lead candidate, TA-46, is targeted at achondroplasia, a form of short-limbed dwarfism that affects approximately one in 25,000 children.

The company is based on research conducted by Elvire Gouze, a senior researcher at Inserm and University of Nice Sophia Antipolis.

The money will go towards advancing TA-46 and Therchon’s portfolio.

In addition to the funding news, Therarchon has also announced Luca Santarelli as its new chief executive. Chahra Louafi, senior investment director and head of the Biotherapies and Rare Diseases Fund at Bpifrance, has joined Therachon’s board of directors.

Luca Santarelli said: “I am excited to join Therachon and look forward to continuing to build a world-class pipeline and partnering with the achondroplasia community to develop a truly transformative therapeutic option.

“Our lead pipeline candidate TA-46 has demonstrated exceptional preclinical efficacy and holds the promise of fully restoring normal growth and mitigating some of the devastating complications in children suffering from achondroplasia.”

See more from this Government Report: France


Copyright Mawsonia Limited 2010. Please don't cut articles from or the PDF and redistribute by email or post to the web without written permission.

Most read

  1. Big deal: British Business Bank launches $500m fund

    February 27, 2017

  2. Scohia Pharma to spin out of Takeda with $87m

    March 15, 2017

  3. Big deal: Airbnb takes series F booking from CIC

    March 13, 2017

  4. News round up 27 February 2017

    February 27, 2017

  5. Wills takes charge of Energy Technologies Institute

    March 07, 2017


  • 23 May - 24 May, 2017

    GCV Symposium 2017 - London

    Join 400+ business leaders from the corporate venturing and wider high growth business ecosystem for the two-day 2017 GCV Symposium.

  • More Events